Maze Therapeutics (MAZE) PT Raised to $50 at Leerink Partners

Leerink Partners analyst Joseph Schwartz raised the price target on Maze Therapeutics (NASDAQ: MAZE) to $50.00 (from $34.00) while maintaining a Outperform rating.

The analyst comments "Ahead of the topline proof-of-concept data from the Ph.2 HORIZON study with MZE829 in AMKD in the first quarter of 2026, we are reviewing the competitive data, the bar for success, and how we think the stock could trade. Despite Maze's outperformance this year (+147% YTD versus +36% for the XBI) after a successful IPO (here) and positive pipeline data (here), we see a favorable set-up into the HORIZON data, with an up/down of +65%/-50% (exhibit 1). The Ph.2 HORIZON study (NCT06830629) explores MZE829 in APOL1-mediated kidney disease (AMKD). MZE829 is an inhibitor of apolipoprotein L1 (APOL1), a mechanism that has been de-risked by Vertex's (VRTX, OP, Risinger) inaxaplin in this indication (albeit data has only been generated to date in APOL1-mediated focal segmental glomerulosclerosis/FSGS). Following our preview, we have increased conviction in MZE829 and its potential for competitive differentiation. As such, we are raising our probability-of-success (PoS) to 65% (from 50%). This increases our PT to $50 (from $34) and we reiterate our Outperform rating. Overall, we continue to hold a favorable view of the Maze story, especially with cash into 2028 and multiple upcoming catalysts across the precision medicines platform."

You May Also Be Interested In

• Silver Lake In Talks To Buy Workday, Sources Say - Reuters
• JPMorgan Downgrades Computershare Limited (CPU:AU) (CMSQY) to Neutral
• Anthropic CFO Krishna Rao is leading early IPO meetings with investors and has not discussed valuation - CNBC